ABSTRACT
A decrease in the ceramide content of the stratum corneum is known to cause dry and barrier-disrupted skin. In this literature review, the clinical usefulness of preparations containing natural or synthetic ceramides for water retention and barrier functions was evaluated. The PubMed, Cochrane Library, and Igaku Chuo Zasshi databases were searched using keywords such as "ceramide", "skincare products", "barrier + hydration + moisture + skin", and "randomized trial". All database searches were conducted in February 2019. Forty-one reports were selected based on the following criterion: comparative control studies that evaluated the effects of ceramide-containing formulations based on statistical evidence. Among the 41 reports, 12 were selected using the patient, intervention, comparison, and outcome approach. These 12 reports showed that external ceramide-containing preparations can improve dry skin and barrier function in patients with atopic dermatitis. However, a double-blinded comparative study with a large sample size is warranted for appropriate clinical use.
Subject(s)
Dermatitis, Atopic , Eczema , Ceramides , Dermatitis, Atopic/drug therapy , Epidermis , Humans , WaterABSTRACT
We established a method for directly measuring mycotoxin ochratoxin A (OTA) in foods by solid-phase fluorescence of monolith-immobilized antibodies. The antibody was introduced onto only one side of an 8 mm-diameter, 3 mm-thick monolith via covalently immobilized protein G. 4 µg (2.7 × 10-11 mol) of antibody was immobilized per one monolith. A maximum of 10 µg (2.4 × 10-11 mol) OTA adsorbed to the activated side of each monolith. The amount of OTA adsorbed and the fluorescence intensity showed good linearity in the range of 0.5-3 ng OTA. Loading the sample solution onto the non-antibody side on the monolith blocked the hydrophobic fluorescent matrices from reaching the immobilized surface of the antibody. The proposed method was able to detect 1 ng OTA/g in solid samples with complex matrices. Mean recoveries obtained at spiked concentration of 3 ng g-1 OTA/g were 78-90% with relative standard deviations of <7.9%.
Subject(s)
Antibodies, Monoclonal/immunology , Carcinogens/analysis , Fluorometry/methods , Ochratoxins/analysis , Adsorption , Fluorescence , Reproducibility of ResultsABSTRACT
The "Guidelines for the management of dermatomycosis" of the Japanese Dermatological Association were first published in Japanese in 2009 and the Guidelines Committee of the Japanese Dermatological Association revised it in 2019. The first guidelines was prepared according to the opinions of the Guidelines Committee members and it was of educational value. The revised version is composed of introductory descriptions of the disease concepts, diagnosis, medical mycology and recent advances in treatment, along with clinical questions (CQ), which is intended to help in general practice for dermatologists. The CQ are limited to those involved in therapy but include some of the recently launched antifungal agents. The level of evidence and the degree of recommendation for each item were reviewed by the committee based on clinical studies published by 2018. For rare dermatomycoses, recommendations by the committee are described in the guidelines. In this field, there are still few good quality studies on treatment. Periodic revision in line with new evidence is necessary.
Subject(s)
Dermatomycoses , Antifungal Agents/therapeutic use , Dermatomycoses/diagnosis , Dermatomycoses/drug therapy , HumansABSTRACT
The Japanese Dermatological Association prepared the clinical guidelines for the "Wound, pressure ulcer and burn guidelines", second edition, focusing on treatments. Among them, "Guidelines for wounds in general" is intended to provide the knowledge necessary to heal wounds, without focusing on particular disorders. It informs the basic principles of wound treatment, before explanations are provided in individual chapters of the guidelines. We updated all sections by collecting references published since the publication of the first edition. In particular, we included new wound dressings and topical medications. Additionally, we added "Question 6: How should wound-related pain be considered, and what should be done to control it?" as a new section addressing wound pain, which was not included in the first edition.
Subject(s)
Pressure Ulcer , Bandages , Humans , Pressure Ulcer/therapy , Wound HealingABSTRACT
"Wound, pressure ulcer and burn guidelines - 6: Guidelines for the management of burns, second edition" is revised from the first edition which was published in the Japanese Journal of Dermatology in 2016. The guidelines were drafted by the Wound, Pressure Ulcer and Burn Guidelines Drafting Committee delegated by the Japanese Dermatological Association, and intend to facilitate physicians' clinical decisions in preventing, diagnosing and treating burn injury. All sections are updated by collecting documents published since the publication of the first edition. Especially, the recommendation levels of dressing materials newly covered by the Japanese national health insurance are mentioned. In addition, the clinical questions (CQ) regarding the initial treatment of electrical (CQ15) and chemical burns (CQ16), and also the use of escharotomy (CQ22), are newly created.
Subject(s)
Pressure Ulcer , Bandages , Humans , Pressure Ulcer/diagnosis , Pressure Ulcer/therapyABSTRACT
The Japanese Dermatological Association prepared guidelines focused on the treatment of skin ulcers associated with connective tissue disease/vasculitis practical in clinical settings of dermatological care. Skin ulcers associated with connective tissue diseases or vasculitis occur on the background of a wide variety of diseases including, typically, systemic sclerosis but also systemic lupus erythematosus (SLE), dermatomyositis, rheumatoid arthritis (RA), various vasculitides and antiphospholipid antibody syndrome (APS). Therefore, in preparing the present guidelines, we considered diagnostic/therapeutic approaches appropriate for each of these disorders to be necessary and developed algorithms and clinical questions for systemic sclerosis, SLE, dermatomyositis, RA, vasculitis and APS.
Subject(s)
Connective Tissue Diseases , Lupus Erythematosus, Systemic , Pressure Ulcer , Skin Diseases, Vascular , Skin Ulcer , Vasculitis , Humans , Skin Ulcer/diagnosis , Skin Ulcer/drug therapy , Skin Ulcer/etiology , Vasculitis/diagnosis , Vasculitis/drug therapySubject(s)
Pressure Ulcer , Bandages , Humans , Pressure Ulcer/diagnosis , Pressure Ulcer/therapy , Wound HealingABSTRACT
Male-pattern hair loss (MPHL, androgenetic alopecia) is a slowly progressive form of alopecia which begins after puberty. In 2010, we published the first Japanese edition of guidelines for the diagnosis and treatment of MPHL. It achieved the original goal of providing physicians and patients in Japan with evidence-based information for choosing efficacious and safe therapy for MPHL. Subsequently, new therapeutic drugs and treatment methods have been developed, and women's perception of MPHL has undergone change and the term "female-pattern hair loss (FPHL)" is becoming more common internationally. Thus, here we report a revised version of the 2010 guidelines aimed at both MPHL and FPHL. In these guidelines, finasteride 1 mg daily, dutasteride 0.5 mg daily and topical 5% minoxidil twice daily for MPHL, and topical 1% minoxidil twice daily for FPHL, are recommended as the first-line treatments. Self-hair transplantation, irradiation by light-emitting diodes and low-level lasers, and topical application of adenosine for MPHL are recommended, whereas prosthetic hair transplantation and oral administration of minoxidil should not be performed. Oral administration of finasteride or dutasteride are contraindicated for FPHL. In addition, we have evaluated the effectiveness of topical application of carpronium chloride, t-flavanone, cytopurine, pentadecane and ketoconazole, and wearing a wig. Unapproved topical application of bimatoprost and latanoprost, and emerging hair regeneration treatments have also been addressed. We believe that the revised guidelines will improve further the diagnostic and treatment standards for MPHL add FPHL in Japan.
Subject(s)
Alopecia/therapy , Hair/transplantation , Low-Level Light Therapy , Adenosine/therapeutic use , Administration, Oral , Administration, Topical , Alopecia/diagnosis , Dutasteride/therapeutic use , Female , Finasteride/therapeutic use , Humans , Japan , Lasers, Semiconductor/therapeutic use , Male , Minoxidil/therapeutic use , Sex Factors , Treatment OutcomeABSTRACT
The Guidelines for the Treatment of Acne Vulgaris of the Japanese Dermatological Association was first published in Japanese in 2008 and revised in 2016 and 2017. These guidelines (GL) indicate the standard acne treatments in Japan and address pharmaceutical drugs and treatments applicable or in use in Japan. In these GL, the strength of the recommendation is based on clinical evidences as well as availability in Japanese medical institutions. In the 2016 and 2017 GL, some of the clinical questions were revised, and other questions were added in accordance with approval of topical medicines containing benzoyl peroxide (BPO). Rather than monotherapies of antibiotics, the 2017 GL more strongly recommend combination therapies, especially fixed-dose combination gels including BPO in the aspects of pharmacological actions and compliance in the acute inflammatory phase to achieve earlier and better improvements. The 2017 GL also indicate to limit the antimicrobial treatments for the acute inflammatory phase up to approximately 3 months and recommend BPO, adapalene, and a fixed-dose combination gel of 0.1% adapalene and 2.5% BPO for the maintenance phase to avoid the emergence of antimicrobial-resistant Propionibacterium acnes. The 2017 GL also discuss rosacea, which requires discrimination from acne and a different treatment plan.
Subject(s)
Acne Vulgaris/drug therapy , Dermatologic Agents/therapeutic use , Dermatology/standards , Societies, Medical/standards , Acne Vulgaris/microbiology , Adapalene/therapeutic use , Administration, Cutaneous , Anti-Bacterial Agents/standards , Anti-Bacterial Agents/therapeutic use , Benzoyl Peroxide/standards , Benzoyl Peroxide/therapeutic use , Dermatologic Agents/standards , Drug Combinations , Drug Resistance, Bacterial , Humans , Japan , Naphthalenes/standards , Naphthalenes/therapeutic use , Propionibacterium acnes/physiology , Treatment OutcomeABSTRACT
Atopic dermatitis is a chronic inflammatory skin disease. The objective of this study was to characterize the burden of atopic dermatitis in Japanese adult patients relative to the general population. Japanese adults (≥18 years) with a self-reported diagnosis of atopic dermatitis and adult controls without atopic dermatitis/eczema/dermatitis were identified from the 2013 Japan National Health and Wellness Survey. Atopic dermatitis patients were propensity-score matched with non-atopic dermatitis controls (1:2 ratio) on demographic variables. Patient-reported outcome data on comorbidities, mood and sleep disorders, health-related quality of life, work productivity and activity impairment, and health-care resource utilization were analyzed in atopic dermatitis patients and matched controls. A total of 638 Japanese adult patients with atopic dermatitis were identified, of whom 290 (45.5%) rated their disease as "moderate/severe" and 348 (54.5%) as "mild". The analysis cohort comprised 634 atopic dermatitis patients and 1268 matched controls. Atopic dermatitis patients reported a significantly higher prevalence of arthritis, asthma, nasal allergies/hay fever, anxiety, depression and sleep disorders compared with controls (all P < 0.001). Atopic dermatitis patients also reported a significantly poorer health-related quality of life, higher overall work and activity impairment, and higher health-care resource utilization (all P < 0.001). Self-rated disease severity was not associated with disease burden, except for a significantly higher overall work and activity impairment. In conclusion, Japanese adult patients with atopic dermatitis reported a substantial disease burden relative to adults without atopic dermatitis, suggesting an unmet need for effective strategies targeting disease management.
Subject(s)
Cost of Illness , Dermatitis, Atopic/epidemiology , Health Surveys/statistics & numerical data , Patient Acceptance of Health Care/statistics & numerical data , Quality of Life , Adult , Case-Control Studies , Cohort Studies , Comorbidity , Dermatitis, Atopic/psychology , Female , Humans , Japan/epidemiology , Male , Middle Aged , Mood Disorders/epidemiology , Prevalence , Respiratory Hypersensitivity/epidemiology , Self Report , Severity of Illness Index , Sleep Wake Disorders/epidemiologyABSTRACT
The proposal by the 1994 International Chapel Hill Consensus Conference on the Nomenclature of Systemic Vasculitides (CHCC1994) and by the CHCC2012 markedly influenced the classification and way of considering cutaneous vasculitis. In the proposal by the CHCC1994, hypersensitivity angiitis was defined as an equivalent pathological condition to microscopic polyangiitis or cutaneous leukocytoclastic angiitis (CLA), and it was not adopted as a disease name. However, CLA which was positioned as a type of small-vessel vasculitis is only a pathological name. In the proposal by the CHCC2012, a new category of single-organ vasculitis included CLA and cutaneous arteritis. Vasculitis allergica cutis (Ruiter) corresponded to CLA and cutaneous polyarteritis nodosa corresponded to cutaneous arteritis. The Japanese Dermatological Association (JDA) prepared guidelines for the management of vasculitis and vascular disorders in 2008 based on the proposal by the CHCC1994 and their original viewpoint of dermatology. The JDA subsequently revised the 2008 edition guidelines in 2016 following publication of the proposal of the CHCC2012 in Japanese. We presented the outline of the 2016 edition guidelines and propose a treatment algorithm for primary vasculitides based on the evaluation of the cutaneous symptoms for cases suspected as primary cutaneous vasculitides, which integrates the 2008 JDA guideline and CHCC2012 classification. This is the secondary English version of the original Japanese manuscript for the guideline for management of vasculitis and vascular disorders published in the Japanese Journal of Dermatology 127(3); 299-415, 2017.
Subject(s)
Dermatology/standards , Skin Diseases, Vascular/therapy , Vasculitis/therapy , Dermatology/methods , Humans , Japan , Skin/blood supply , Skin/pathology , Skin Diseases, Vascular/classification , Skin Diseases, Vascular/pathology , Vasculitis/classification , Vasculitis/pathologyABSTRACT
BI 1002494 [(R)-4-{(R)-1-[7-(3,4,5-trimethoxy-phenyl)-[1,6]napthyridin-5-yloxy]-ethyl}pyrrolidin-2-one] is a novel, potent, and selective spleen tyrosine kinase (SYK) inhibitor with sustained plasma exposure after oral administration in rats, which qualifies this molecule as a good in vitro and in vivo tool compound. BI 1002494 exhibits higher potency in inhibiting high-affinity IgE receptor-mediated mast cell and basophil degranulation (IC50 = 115 nM) compared with B-cell receptor-mediated activation of B cells (IC50 = 810 nM). This may be explained by lower kinase potency when the physiologic ligand B-cell linker was used, suggesting that SYK inhibitors may exhibit differential potency depending on the cell type and the respective signal transduction ligand. A 3-fold decrease in potency was observed in rat basophils (IC50 = 323 nM) compared with human basophils, but a similar species potency shift was not observed in B cells. The lower potency in rat basophils was confirmed in both ex vivo inhibition of bronchoconstriction in precision-cut rat lung slices and in reversal of anaphylaxis-driven airway resistance in rats. The different cellular potencies translated into different in vivo efficacy; full efficacy in a rat ovalbumin model (that contains an element of mast cell dependence) was achieved with a trough plasma concentration of 340 nM, whereas full efficacy in a rat collagen-induced arthritis model (that contains an element of B-cell dependence) was achieved with a trough plasma concentration of 1400 nM. Taken together, these data provide a platform from which different estimates of human efficacious exposures can be made according to the relevant cell type for the indication intended to be treated.
Subject(s)
B-Lymphocytes/drug effects , B-Lymphocytes/enzymology , Basophils/drug effects , Basophils/enzymology , Naphthyridines/pharmacology , Protein Kinase Inhibitors/pharmacology , Pyrrolidines/pharmacology , Pyrrolidinones/pharmacology , Syk Kinase/antagonists & inhibitors , Administration, Oral , Animals , Humans , Male , Mast Cells/drug effects , Mast Cells/enzymology , Naphthyridines/administration & dosage , Protein Kinase Inhibitors/administration & dosage , Pyrrolidines/administration & dosage , Pyrrolidinones/administration & dosage , RatsABSTRACT
The Wound/Burn Guidelines Committee consists of members commissioned by the Board of Directors of the Japanese Dermatological Association (JDA). It held several meetings and evaluations in writing since October 2008, and drafted five guidelines for the diagnosis and treatment including commentaries on wounds in general and the Guidelines for the Diagnosis and Treatment for Pressure Ulcers by taking opinions of the Scientific Committee and Board of Directors of JDA into consideration.
Subject(s)
Burns/diagnosis , Burns/therapy , Pressure Ulcer/diagnosis , Pressure Ulcer/therapy , Wound Healing , Administration, Cutaneous , Bandages , Debridement , Dermatology/standards , Diagnosis, Differential , Evidence-Based Practice/standards , Humans , Japan , Ointments , Pain Management/methods , Patient Positioning , Pressure Ulcer/prevention & control , Pressure Ulcer/surgery , Skin Care/methodsABSTRACT
The Japanese Dermatological Association prepared guidelines focused on the treatment of skin ulcers associated with connective tissue disease/vasculitis practical in clinical settings of dermatological care. Skin ulcers associated with connective tissue diseases or vasculitis occur on the background of a wide variety of diseases including, typically, systemic sclerosis but also systemic lupus erythematosus (SLE), dermatomyositis, rheumatoid arthritis (RA), various vasculitides and antiphospholipid antibody syndrome (APS). Therefore, in preparing the present guidelines, we considered diagnostic/therapeutic approaches appropriate for each of these disorders to be necessary and developed algorithms and clinical questions for systemic sclerosis, SLE, dermatomyositis, RA, vasculitis and APS.
Subject(s)
Calcinosis/complications , Connective Tissue Diseases/complications , Skin Ulcer/drug therapy , Vasculitis/complications , Antithrombins/therapeutic use , Calcinosis/diagnosis , Calcinosis/therapy , Calcium Channel Blockers/therapeutic use , Dapsone/therapeutic use , Endothelin Receptor Antagonists/therapeutic use , Glucocorticoids/therapeutic use , Humans , Immunosuppressive Agents/therapeutic use , Leukapheresis , Phosphodiesterase 5 Inhibitors/therapeutic use , Platelet Aggregation Inhibitors/therapeutic use , Prostaglandins/therapeutic use , Skin Ulcer/etiology , Skin Ulcer/surgery , Tumor Necrosis Factor-alpha/antagonists & inhibitorsABSTRACT
The Japanese Dermatological Association determined to prepare the Wound/Burn Guidelines focusing on treatments, catering to needs for the clinical practice of dermatology. Among these guidelines, "Wounds in General" was intended to explain knowledge necessary "to heal wounds" without specifying particular disorders.
Subject(s)
Anti-Infective Agents, Local/therapeutic use , Burns/therapy , Disinfection/methods , Therapeutic Irrigation/methods , Wound Healing , Wounds and Injuries/therapy , Administration, Cutaneous , Anti-Infective Agents, Local/administration & dosage , Chronic Disease , Humans , Japan , Societies, Medical , Therapeutic Irrigation/standards , Wounds and Injuries/classification , Wounds and Injuries/diagnosisABSTRACT
We aimed to prepare guidelines for the management of diabetic ulcer/gangrene with emphasis on the diagnosis and treatment of skin symptoms. They serve as a tool to improve the quality of the diagnosis and treatment in each patient and, further, to improve the level of the care for diabetic ulcer in Japan by systematically presenting evidence-based recommendations for clinical judgments by incorporating various viewpoints.
Subject(s)
Diabetic Foot/therapy , Gangrene/therapy , Aldehyde Reductase/antagonists & inhibitors , Anti-Bacterial Agents/administration & dosage , Blood Component Removal , Debridement , Diabetic Foot/complications , Diabetic Foot/diagnosis , Diabetic Nephropathies/diagnosis , Gangrene/diagnosis , Gangrene/etiology , Humans , Hyperbaric Oxygenation , Ischemia/diagnosis , Ischemia/etiology , Negative-Pressure Wound Therapy , Orthotic Devices , Osteomyelitis/diagnostic imaging , Osteomyelitis/drug therapy , Osteomyelitis/etiology , Renal Dialysis/adverse effects , Wound HealingABSTRACT
Varicose veins are treated at multiple clinical departments, but as patients often visit the dermatology clinic first due to leg ulcers, the present Guidelines for the Management of Lower Leg Ulcers/Varicose Veins were prepared in consideration of the importance of the dermatologist's role. Also, the disease concept of chronic venous insufficiency or chronic venous disorders and the CEAP classification of these disorders are presented. The objective of the present guidelines is to properly guide the diagnosis and treatment of lower leg ulcers/varicose veins by systematically presenting evidence-based recommendations that support clinical decisions.
Subject(s)
Leg Ulcer/therapy , Varicose Ulcer/therapy , Varicose Veins/therapy , Algorithms , Dermatology , Humans , Japan , Leg Ulcer/classification , Leg Ulcer/diagnosis , Sclerotherapy , Societies, Medical , Stockings, Compression , Varicose Ulcer/classification , Varicose Ulcer/diagnosis , Varicose Veins/classification , Varicose Veins/diagnosis , Vascular Surgical ProceduresABSTRACT
Burns are a common type of skin injury encountered at all levels of medical facilities from private clinics to core hospitals. Minor burns heal by topical treatment alone, but moderate to severe burns require systemic management, and skin grafting is often necessary also for topical treatment. Inappropriate initial treatment or delay of initial treatment may exert adverse effects on the subsequent treatment and course. Therefore, accurate evaluation of the severity and initiation of appropriate treatment are necessary. The Guidelines for the Management of Burn Injuries were issued in March 2009 from the Japanese Society for Burn Injuries as guidelines concerning burns, but they were focused on the treatment for extensive and severe burns in the acute period. Therefore, we prepared guidelines intended to support the appropriate diagnosis and initial treatment for patients with burns that are commonly encountered including minor as well as moderate and severe cases. Because of this intention of the present guidelines, there is no recommendation of individual surgical procedures.